Carthona Capital

Equity Venture Partners is an early-stage venture capital firm investing in B2B software companies across Australia and New Zealand.

The CSIRO Innovation Fund (managed by and trading as Main Sequence Ventures) is a deeptech fund, investing in companies translating research into global-scale businesses. Main Sequence Ventures knows that this takes more than money. We have our genesis in CSIRO and have access to a deep well of data scientists, physicists, synthetic biologists, chemists, astronomers and experts in other disciples. Each member of the management team has been an entrepreneur and understands the difficulties of building a company. We are here to help. We work harder to understand the world that these founders imagine. We are as comfortable in the lab as we are on the front-line with customers. We will invest capital, and ourselves, to systematically reduce risk and increase opportunity by combining the operational velocity of startups with the deep curiosity of Australia's research sector.

Uniseed manages Commercialisation and Venture Funds that invest in companies commercialising research from university and research partners, including early-stage deep-tech and life-sciences businesses.

Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.

Alium Capital Management invests in technology and innovation companies across private, secondary and listed markets. Its Innovation Fund targets private companies and generally takes founder-aligned minority stakes as a first institutional investor.

Square Peg is a venture capital firm that invests in emerging technology companies across the internet economy in Australia and New Zealand, Southeast Asia, and Israel.

Blackbird is an Australia and New Zealand venture capital firm backing ambitious technology companies from the earliest stages through later growth. It invests across software, deep tech, climate, fintech, health and other technology-led sectors, with portfolio companies including Canva, SafetyCulture, Culture Amp, Zoox and Halter.

AirTree Ventures is an early and growth stage venture firm that invests in technology-enabled Australian and New Zealand companies. We invest at all stages of the startup lifecycle and love to write the first cheque for a promising young company. Airtree looks for world-class entrepreneurs who want to build iconic companies, and we do everything we can to assist in realising that vision. The AirTree team are entrepreneurs ourselves and have started companies whilst running big businesses across the globe. We understand what it takes to build a world-class company. The founders of our investee companies are everything to us. They are the foundation of what we do. We have rolled up our sleeves beside them and helped dozens of entrepreneurs achieve great outcomes over two decades. Our experience and hands on approach sets us apart from other investors. We are not just bobbing heads or cheerleaders. As a great founder you will always decide the path, you know your sector more intimately than we do. But we think it can be healthy to have a spirited, fact-based conversation first. In the past, we have had success investing in marketplaces, global SaaS businesses, next generation finance, digital commerce, and media and marketing platforms. Ultimately, we invest in disruptive businesses in any sector looking to reshape traditional industries and we support you to achieve your vision.

Artesian's venture business manages dedicated and pooled venture funds and institutional mandates, investing in early-stage companies across climate and energy, agrifood, health, AI, defence and frontier themes.

Titanium Ventures is an independent venture capital firm investing in high-potential technology startups, including companies using software and AI.

OneVentures is an Australian investment manager with technology growth-equity and clinical-stage life-sciences investment pillars, alongside a growth-credit practice providing debt facilities to technology companies.